The global spatial OMICS market size was valued at USD 225.81 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10.00% from 2021 to 2028. Understanding cells and their nucleic acid content in their morphological context is critical for establishing a link between disease and genome architecture, thus boosting the interest of translational researchers in spatial OMICS and associated technologies. The extensive research for understanding the COVID-19 infection has turned the attention to the application of spatial transcriptomic and other omics studies. For instance, in October 2020, a group of researchers from the Massachusetts General Hospital used spatial transcriptomics technology for analyzing the autopsy specimens obtained from around 24 COVID-19 patients to understand the SARS-CoV-2 infection.
Several companies operating in the market offer a wide range of solutions for spatial omics studies. For instance, NanoString manufactured GeoMx Digital Spatial Profiler (DSP), which helps in the quantification of around 1,800 RNA targets, including COVID-19 proteases and receptors.
In addition, with the system, researchers generated large data sets of tissue images and molecular data obtained from COVID-19 decedents and compared them with the patients who passed away from similar diseases, such as MERS-CoV (2012), SARS-CoV, and other non-viral causes, which facilitated a better understanding of the COVID-19 infection.
Cancer immunotherapy is one of the major drivers of the market. It is essential to conduct spatial multi-omics studies for understanding tumor immunogenicity of the complex tumor microenvironment. Companies are focusing on developing transformational approaches for cancer biomarker discovery.
For instance, in March 2021, Akoya Biosciences, Inc. collaborated with the Bloomberg Center for Physics and Astronomy and Bloomberg-Kimmel Institute for Cancer Immunotherapy (BKI) at the Johns Hopkins University School of Medicine. This involved the use of Akoya’s Phenoptics multiplex immunofluorescence (mIF) platform by BKI for spatial profiling of tissue sections.
The spatial transcriptomics segment dominated the market with a share of 63.56% in 2020. Continuous advancements in sequencing technologies have accelerated the transcriptomic study of single cells. For the comprehensive study of multicellular organisms, efforts are being taken to design novel solutions for high-throughput genomic analysis while maintaining the spatial information of the sample/tissue under observation or subcellular localization of analyzed DNA/RNA.
The development of various in situ methods enhances the capabilities to explore spatial information in biological investigation. These methods have led to the convergence of function-oriented fields of biochemistry and molecular genetics with structure-focused fields such as histology and embryology, thereby enabling spatially resolved molecular investigation of biological processes.
For example, a combination of in situ hybridization techniques with genetic tools helps explore the formation of gene expression gradients along with embryonic axes at different developmental stages. The gradient formation helps in understanding embryonic development and organ formation. The spatial genomics segment is expected to expand at the fastest CAGR throughout the forecast period. FISH is the most commonly used method for spatial genomics.
The consumables segment accounted for the largest share of 53.01% in 2020 owing to the high utilization rate and launch of novel products. For instance, in March 2021, Bruker launched new consumables for the chemical cross-linking of proteins (XL-MS). The new PhoX cross-linker facilitates the purification of protein from XL-MS reaction complex mixtures. Moreover, the company plans to launch three cleavable cross-linkers for cleaving the cross-linkers generated in MS experiments.
The launch of new instruments is directly associated with the development of the consumables. Therefore, this drives the instruments as well as the consumables segment. In December 2020, NanoString announced the development of spatial molecular imager (SMI). It is a next-generation spatial OMICS platform designed for multiplexed protein and RNA analysis for single cells in FFPE tissue samples. The platform is expected to be launched by 2022.
The growth of the software segment is attributed to the extensive use of tools for the analysis of single-cell omics data. For instance, in January 2021, researchers from the U.S. used GLUER (inteGrative anaLysis of mUlti-omics at single-cEll Resolution), a tool that integrated the imaging data with single-cell omics data. The new tool has proved to be efficient in accurately matching cells across a broad range of data modalities.
The instrumental analysis segment dominated the market with a revenue share of 47.69% in 2020. The growth of the segment can be primarily attributed to substantial advancements being performed in instruments such as microscopy and mass spectrometry. Mass spectrometry is one of the most promising tools that is used for quantifying nucleic acid and proteins.
It has several advantages such as high resolution, high speed, and high-throughput operations for profiling of protein, which are later used for analyzing complex biological samples. This facilitates novel applications such as new drug development, biomarker discovery, and diagnostics.
The data analysis segment is expected to witness lucrative growth over the forecast period owing to the increasing integration of advanced computational solutions for generating detailed spatial information for omics studies. In addition, the development and launch of new platforms are contributing to the segment growth. For instance, in April 2021, Vizgen received a grant of USD 37 million to enhance the commercialization of its MERSCOPE platform.
The formalin fixation and paraffin-embedding (FFPE) segment held the largest share of 57.26% in 2020. FFPE is considered a standard sample type that is most used for the preservation of human tissue for clinical diagnosis, and hence it holds a major share in the global market. This technique is considered the best in researching tissue morphology for clinical histopathology and diagnostic purposes.
In addition, FFPE specimens are found in abundance in clinical tissue banks, which contributes to the segment growth. However, they are incompatible with single-cell level transcriptome sequencing owing to RNA degradation and RNA damage during storage and extraction. Hence, researchers are focusing on new approaches for increasing the application of FFPE in spatial transcriptomic studies.
The academic and translational research institutes segment dominated the market with a revenue share of 89.60% in 2020. An increase in the adoption of spatial OMICS to translate real-time tissue responses to an external agent increases the technology’s adoption in translational research. Translational studies in the field of genomics help researchers and healthcare practitioners analyze the behavior of human tissues and cells from different individuals in different environments.
This vital information may lead to the evolution of new and better ways to prevent diseases. For instance, single-cell transcriptomics is found to be useful for neuroscientists to understand cell types forming the brain. These methods help understand the spatial architecture of nervous tissues and evaluate the brain’s function. However, this further requires linking molecular cell types to physiological, morphological, and behavioral factors.
Spatially resolved transcriptomics methods play a fundamental role to fill this gap by localizing molecularly defined tissue or cell types, with simultaneous detection of activity, morphology, and connectivity. Therefore, most of the research organizations have launched study programs to leverage the applications of spatial transcriptomics in the field of neuroscience. Some of these programs include the Human Cell Atlas initiative, European Human Brain Project, and BRAIN Initiative launched by the NIH.
North America accounted for the largest share of 44.80% in 2020. This can be attributed to the increasing prevalence of cancer, the growing demand for personalized medicine, well-developed healthcare facilities, and the availability of novel diagnostic techniques. The growing morbidity and mortality rates due to cancer and other metabolic, autoimmune, and inflammatory disorders have led to an increase in the need for developing novel therapies, thereby driving the market in this region.
In addition, companies operating in North America are launching new initiatives and programs for discovering and increasing translational applications, which is further contributing to the market growth. For instance, in March 2021, NanoString Technologies, Inc. launched the Technology Access Program (TAP) through which the company will analyze tissue samples of patients using the Spatial Molecular Imager platform and GeoMx Digital Spatial Profiler. Hence, such initiatives help in expanding spatial biology applications in the region.
Asia Pacific is expected to expand at the fastest CAGR from 2021 to 2028. Companies are entering into agreements for expanding their biological research activities, which, in turn, will drive the adoption of omics tools in the region. For instance, in February 2021, ERS Genomics Limited granted access to its CRISPR/Cas9 patent portfolio to G+FLAS Life Sciences, Inc. - a South Korea-based biotechnology start-up. This agreement helped the company in developing genome editing applications with CRISPR/Cas9.
10x Genomics is a leading player in the global market. The company has set off the trend for spatial transcriptomics with the launch of the Visium Spatial Gene Expression platform. In addition, the company acquired Cartana AB and ReadCoor in 2020 for in situ analysis. These acquisitions brought more than 100 patents to the company and it is expected that 10x Genomics will use these patents to develop a novel in situ analysis platform.
Other prominent market players have adopted growth strategies to enhance their market presence. For instance, Bruker Corporation has made a strategic investment in spatial biology in March 2021. With this investment, the company plans to expand and develop novel spatial analysis technologies to empower researchers to advance discovery and delve deeper into translational and life science research. Some prominent players in the global spatial OMICS market include:
S2 Genomics, Inc.
NanoString Technologies, Inc.
Seven Bridges Genomics
Millennium Science Pty Ltd.
Akoya Biosciences, Inc.
Brooks Automation, Inc.
Market size value in 2021
USD 262.41 million
Revenue forecast in 2028
USD 484.22 million
CAGR of 10.0% from 2021 to 2028
Base year for estimation
2017 - 2019
2021 - 2028
Revenue in USD million and CAGR from 2021 to 2028
Revenue forecast, company share, competitive landscape, growth factors, and trends
Technology, product, workflow, sample type, end use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; U.K.; France; Spain; Italy; Netherlands; Japan; China; India; South Korea; Australia; Singapore; Brazil; South Africa
10x Genomics; Dovetail Genomics; S2 Genomics, Inc.; NanoString Technologies, Inc.; Seven Bridges Genomics; PerkinElmer, Inc.; Bio-Techne; Danaher Corporation; IonPath, Inc.; Millennium Science Pty Ltd.; Akoya Biosciences, Inc.; Fluidigm Corporation; Diagenode Diagnostics; Biognosys AG; Rebus Biosystems; Ultivue, Inc.; Vizgen Corp.; BioSpyder Technologies; Bruker; Brooks Automation, Inc.
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global spatial OMICS market report on the basis of technology, product, workflow, sample type, end use, and region:
Technology Outlook (Revenue, USD Million, 2017 - 2028)
Laser capture microdissection (LCM), by tissue type
FFPE tissue samples
Transcriptome in-vivo analysis (TIVA)
In situ sequencing
Microscopy-based RNA Imaging Techniques, by methods
Single Molecule RNA Fluorescence In-Situ Hybridization (smFISH)
Padlock Probes/ Rolling Circle Amplification
Branched DNA probes
Microscopy-based Live DNA Imaging
Genome Perturbation Tools
Multiplexed Ion Beam Imaging
Product Outlook (Revenue, USD Million, 2017 - 2028)
Storage and management databases
Workflow Outlook (Revenue, USD Million, 2017 - 2028)
Sample Type Outlook (Revenue, USD Million, 2017 - 2028)
End-use Outlook (Revenue, USD Million, 2017 - 2028)
Academic & Translational Research Institutes
Pharmaceutical and Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2017 - 2028)
b. The consumables segment accounted for the largest share of 53.01% in 2020 owing to the high utilization rate and launch of novel products in the spatial OMICS market.
b. The instrumental analysis segment dominated the spatial OMICS market with a revenue share of 47.69% in 2020.
b. The formalin fixation and paraffin-embedding (FFPE) segment held the largest share of 57.26% in 2020 in the spatial OMICS market.
b. The academic and translational research institutes segment dominated the spatial OMICS market with a revenue share of 89.60% in 2020.
b. North America accounted for the largest share of 44.80% in 2020 in the spatial OMICS market.
b. The global spatial OMICS market size was estimated at USD 225.81 million in 2020 and is expected to reach USD 262.41 million in 2021.
b. The global spatial OMICS market is expected to grow at a compound annual growth rate of 10.0% from 2021 to 2028 to reach USD 484.22 million by 2028.
b. The spatial transcriptomics segment dominated the spatial OMICS market with a share of 63.56% in 2020.
b. Some key players operating in the spatial OMICS market include 10x Genomics; Dovetail Genomics; S2 Genomics, Inc; NanoString Technologies, Inc; Seven Bridges Genomics; PerkinElmer, Inc; Bio-Techne; Danaher Corporation; IonPath, Inc; Millennium Science Pty Ltd; Akoya Biosciences, Inc; Fluidigm Corporation; Diagenode Diagnostics; Biognosys AG; Rebus Biosystems; Ultivue, Inc; Vizgen Corp; BioSpyder Technologies; Bruker; and Brooks Automation, Inc.
b. Key factors that are driving the spatial OMICS market growth include the emerging potential of spatial omic analysis as a cancer diagnostic tool, the advent of the fourth generation of sequencing (in situ sequencing), and a rise in competitiveness amongst emerging players.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."